vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Syndax Pharmaceuticals Inc is the larger business by last-quarter revenue ($68.5M vs $43.5M, roughly 1.6× DYNEX CAPITAL INC). On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 531.3%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
DX vs SNDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $68.5M |
| Net Profit | — | $-68.0M |
| Gross Margin | — | — |
| Operating Margin | — | -91.3% |
| Net Margin | — | -99.3% |
| Revenue YoY | 531.3% | 791.7% |
| Net Profit YoY | — | 27.8% |
| EPS (diluted) | $1.59 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $68.5M | ||
| Q3 25 | $30.6M | $45.9M | ||
| Q2 25 | $23.1M | $38.0M | ||
| Q1 25 | $17.1M | $20.0M | ||
| Q3 24 | — | $12.5M | ||
| Q1 24 | $-3.2M | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 |
| Q4 25 | — | $-68.0M | ||
| Q3 25 | $150.4M | $-60.7M | ||
| Q2 25 | $-13.6M | $-71.8M | ||
| Q1 25 | $-3.1M | $-84.8M | ||
| Q3 24 | — | $-84.1M | ||
| Q1 24 | $40.1M | $-72.4M | ||
| Q3 23 | — | $-51.1M | ||
| Q2 23 | — | $-44.6M |
| Q4 25 | — | -91.3% | ||
| Q3 25 | — | -125.2% | ||
| Q2 25 | — | -182.7% | ||
| Q1 25 | — | -417.9% | ||
| Q3 24 | — | -716.6% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -99.3% | ||
| Q3 25 | 491.3% | -132.4% | ||
| Q2 25 | -58.8% | -189.3% | ||
| Q1 25 | -18.0% | -423.3% | ||
| Q3 24 | — | -673.0% | ||
| Q1 24 | -1256.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $1.59 | $-0.78 | ||
| Q3 25 | $1.08 | $-0.70 | ||
| Q2 25 | $-0.14 | $-0.83 | ||
| Q1 25 | $-0.06 | $-0.98 | ||
| Q3 24 | — | $-0.98 | ||
| Q1 24 | $0.64 | $-0.85 | ||
| Q3 23 | — | $-0.73 | ||
| Q2 23 | — | $-0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $64.6M |
| Total Assets | $17.3B | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $394.1M | ||
| Q3 25 | $491.0M | $436.0M | ||
| Q2 25 | $387.5M | $455.2M | ||
| Q1 25 | $327.4M | $512.2M | ||
| Q3 24 | — | $389.6M | ||
| Q1 24 | $295.7M | $434.6M | ||
| Q3 23 | — | $363.6M | ||
| Q2 23 | — | $398.8M |
| Q4 25 | $2.5B | $64.6M | ||
| Q3 25 | $2.0B | $115.4M | ||
| Q2 25 | $1.6B | $157.4M | ||
| Q1 25 | $1.4B | $215.1M | ||
| Q3 24 | — | $366.4M | ||
| Q1 24 | $958.5M | $491.9M | ||
| Q3 23 | — | $359.2M | ||
| Q2 23 | — | $400.0M |
| Q4 25 | $17.3B | $529.7M | ||
| Q3 25 | $14.2B | $551.8M | ||
| Q2 25 | $11.3B | $596.1M | ||
| Q1 25 | $9.0B | $640.7M | ||
| Q3 24 | — | $425.8M | ||
| Q1 24 | $6.3B | $543.0M | ||
| Q3 23 | — | $399.2M | ||
| Q2 23 | — | $431.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $-69.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $-69.5M | ||
| Q3 25 | $68.3M | $-70.5M | ||
| Q2 25 | $31.9M | $-87.8M | ||
| Q1 25 | $6.4M | $-95.2M | ||
| Q3 24 | — | $-62.3M | ||
| Q1 24 | $-17.1M | $-83.5M | ||
| Q3 23 | — | $-44.7M | ||
| Q2 23 | — | $-35.4M |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | -0.43× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
